Aims: The pharmacokinetic (PK) profiles of voriconazole in intensive care unit (ICU) patients differ from that in other patients. We aimed to develop a population pharmacokinetic (PopPK) model to evaluate the effects of using extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) and those of various biological covariates on the voriconazole PK profile. Methods: Modeling analyses of the PK parameters were conducted using the nonlinear mixed-effects modeling method (NONMEM) with a two-compartment model. Monte Carlo simulations (MCSs) were performed to observe the probability of target attainment (PTA) when receiving CRRT or not under different dosage regimens, different stratifications of quick C-reactive protein (qCRP), and different minimum inhibitory concentration (MIC) ranges. Results: A total of 408 critically ill patients with 746 voriconazole concentration–time data points were included in this study. A two-compartment population PK model with qCRP, CRRT, creatinine clearance rate (CLCR), platelets (PLT), and prothrombin time (PT) as fixed effects was developed using the NONMEM. Conclusions: We found that qCRP, CRRT, CLCR, PLT, and PT affected the voriconazole clearance. The most commonly used clinical regimen of 200 mg q12h was sufficient for the most common sensitive pathogens (MIC ≤ 0.25 mg/L), regardless of whether CRRT was performed and the level of qCRP. When the MIC was 0.5 mg/L, 200 mg q12h was insufficient only when the qCRP was <40 mg/L and CRRT was performed. When the MIC was ≥2 mg/L, a dose of 300 mg q12h could not achieve ≥ 90% PTA, necessitating the evaluation of a higher dose.
To investigate the relationship between ganciclovir trough concentration and its clinical efficacy and safety in patients with pulmonary cytomegalovirus (CMV) infection and to evaluate the target value of therapeutic drug monitoring (TDM) for predicting clinical efficacy or toxicity, an observational study was conducted on patients with CMV lung infection between Jan. 2021 and Dec. 2023. Target trough ganciclovir concentrations were collected during TDM, and clinical outcomes and adverse events (AEs) were assessed. Multiple regression analyses or binary logistic regression were used to analyze the factors affecting ganciclovir trough concentrations and clinical efficacy. The receiver operating characteristic (ROC) curve analysis identified ganciclovir trough concentration cutoffs as predictors of toxicity. Of 149 included patients, only 19.22% of trough concentrations reached the target range of 2–4 μg/mL. Diabetes, organ transplantation, and elevated hemoglobin levels decrease trough concentrations, whereas elevated blood creatinine and continuous renal replacement therapy (CRRT) increase trough concentrations. No relationship was found between the trough concentrations and the clinical outcomes. Organ transplantation, duration of ganciclovir administration, and albumin levels affect clinical efficacy. The ROC analysis identified ganciclovir trough concentrations of 0.985 (AUC = 0.600) and 0.995 µg/mL (AUC = 0.701) to be associated with decreased hemoglobin and elevated blood creatinine levels, respectively. No association was observed between ganciclovir trough concentration and clinical efficacy. However, thresholds for ganciclovir trough concentrations causing decreased hemoglobin and increased blood creatinine levels were identified. Renal replacement therapy is more likely to lead to elevated trough concentrations of ganciclovir. These findings suggest the importance of TDM for ganciclovir, and a new target range should be considered. IMPORTANCE: An observational study investigated the relationship between ganciclovir trough concentrations and clinical efficacy and safety. Only 19.22% of ganciclovir trough concentrations reached the target range of 2.0–4.0 μg/mL. Diabetes, organ transplantation, and elevated hemoglobin decreased trough concentrations, while elevated creatinine and CRRT increased concentrations. No relationship was found between ganciclovir trough concentrations and clinical outcomes in CMV lung infection. Organ transplantation, duration of ganciclovir administration, and albumin levels affected the clinical efficacy of ganciclovir. Critical ganciclovir trough concentrations of 0.985 and 0.995 μg/mL were associated with toxicity. The findings suggest the importance of therapeutic drug monitoring (TDM) with ganciclovir treatment.
Background: Voriconazole (VCZ) served as primary therapy for invasive aspergillosis in lung transplant recipients. However, VCZ‐induced hepatotoxicity emerged as a frequent adverse effect that critically compromised postoperative management and complication prevention in this vulnerable population. Methods: We performed population pharmacokinetic/pharmacodynamic (PK/PD) modeling using nonlinear mixed‐effects methodology. The analysis included a one‐compartment PK model with alkaline phosphatase (ALP) as the primary hepatotoxicity biomarker. Monte Carlo simulations assessed the effects of dosing regimens on ALP dynamics across various covariate scenarios. Results: The final PK/PD model indicated an apparent systemic clearance of 3.09 L/h and a central volume of 80.31 L. The exposure–response relationship was described using an indirect response model, with the pharmacological effect linked to increases in ALP levels. The maximum drug effect (E max ) was 188.78. The rate constant for psoriatic plaque production (K in ) was 0.31/day, while the rate for plaque loss (K out ) was 0.53/day. Creatinine clearance (CrCL) was identified as a key covariate for apparent clearance, while weight and tacrolimus (TAC) trough level were significant for Emax. The average probability of target attainment for optimized regimens reached 50.2% across all covariate combinations. Clinical simulations identified 100 mg twice daily (bid) as the optimal maintenance dose for hepatotoxicity prevention. Weight‐based dose reduction was recommended for recipients below 50 kg, with stringent therapeutic drug monitoring of TAC concentrations. Conclusion: Our population PK/PD model provides clinically actionable guidance for VCZ dose optimization, particularly for underweight lung transplant recipients on maintenance therapy. The model effectively predicts and prevents VCZ‐induced hepatotoxicity while maintaining therapeutic efficacy.